Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 10/2014

01-10-2014 | Large Intestine (B Cash, Section Editor)

Health Maintenance and Inflammatory Bowel Disease

Authors: Catherine S. Manolakis, Brooks D. Cash

Published in: Current Gastroenterology Reports | Issue 10/2014

Login to get access

Abstract

Inflammatory bowel disease (IBD) patients, specifically those with Crohn’s disease and ulcerative colitis, are at an increased risk of developing adverse events either related to disease course or therapeutic interventions. These risks can be mitigated by ensuring the patient is current on all aspects of their general health maintenance. This article is intended to serve as a guide regarding the health maintenance issues of the patient with IBD with recommendations for screening and surveillance intervals.
Literature
1.
Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventative care for inflammatory bowel disease patients? Dig Dis Sci. 2011;56:819–24.PubMedCrossRef
2.••
Di Palma JA, Farraye FA. Crohn’s disease: the first visit. Gasteroenterol Hepatol. 2011;7:163–9. An important review for the initiation and titration of immunomodulating medications.
3.
Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135–9.PubMedCrossRef
4.
Knox DL, Schachat AP, Mustonen E. Primary, secondary, coincidental ocular complications of Crohn’s disease. Ophthalmology. 1984;91:163–73.PubMedCrossRef
5.
Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Opthalmol. 1982;14:256–360.
6.
Manolakis C, Farraye FA, Di Palma JA. Crohn’s disease: the subsequent visit. Gastroenterol Hepatol. 2013;9:17–20.
7.
Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2, CD008794.PubMed
8.
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.PubMedCrossRefPubMedCentral
9.••
Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9. Important information regarding adverse effects of therapy; differs from what was previously reported. PubMedCrossRefPubMedCentral
10.
Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for nonmelanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–74.PubMedCrossRefPubMedCentral
11.
Bernstein CN. Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:152–6.PubMedCrossRef
12.••
Targownik L, Bernstein C, Nugent Z, Leslie W. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol. 2013;11:278–85. Interesting pathophysiologic review of osteoporosis in IBD. PubMedCrossRef
13.
Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995;10:250–6.PubMedCrossRef
14.
Motley RJ, Clements D, Evans WD, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner. 1993;23:95–104.PubMedCrossRef
15.
Abitol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995;108:417–22.CrossRef
16.
Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313–9.PubMedCrossRefPubMedCentral
17.
Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684–94.PubMedCrossRef
18.
Driscoll Jr RH, Meredith SC, Sitrin M, et al. Vitamin D deficiency and bone disease in patients with Crohn’s disease. Gastroenterology. 1982;83:1252–8.PubMed
19.
Krawitt EL, Beeken WL, Janney CD. Calcium absorption in Crohn’s disease. Gastroenterology. 1976;71:251–4.PubMed
20.
Kuwabara A, Tanaka K, Tsugawa N, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009;20:935–42.PubMedCrossRef
21.
Silvennoinen J, Lamberg-Allardt C, Kakkainen M, et al. Dietar calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med. 1996;240:285–92.PubMedCrossRef
22.
Vagianos K, Bector S, Mcconnell J, et al. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007;31:311–9.PubMedCrossRef
23.
Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631–6.PubMedCrossRef
24.
Sing TT, Demets AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case–control study. Gastroenterology. 2009;136:451–8.CrossRef
25.
Sinclair J, Wasan S, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin N Am. 2012;41:325–37.CrossRef
26.
Cosnes J. What is the link between the use of tobacco and IBD? Inflamm Bowel Dis. 2008;14 suppl 2:S14–5.PubMedCrossRef
27.
Franchimont DP, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol. 1998;10:821–5.PubMedCrossRef
28.
Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity and comorbity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–27.PubMedCrossRefPubMedCentral
29.
Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15:1399–409.PubMedCrossRef
30.
Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55 suppl 1:36–58.CrossRef
31.
32.
Graff L, Walker J, Bernstein C. It’s not just about the gut: managing depression and anxiety in inflammatory bowel disease. Pract Gastroenterol. 2011;62:11–25.
33.
Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumor necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19–30.PubMedCrossRef
34.
Pai M, Zwerling A, Menziers D. Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.PubMedCrossRefPubMedCentral
35.
Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619–33.PubMedCrossRef
36.
Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–40.PubMedCrossRef
37.
Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17:2536–40.PubMedCrossRef
38.
Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18:261–8.PubMedCrossRefPubMedCentral
39.
Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of innumosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042–7.PubMedCrossRef
40.
Rahier JF, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60:456–62.
41.
Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231–8.PubMedCrossRef
42.
Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States. Ann Intern Med. 2012;156:211–7.CrossRef
43.••
Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43–9. Evolving information regarding live vaccines. PubMedPubMedCentral
44.
Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1–30.PubMed
45.
46.
Singh A, Englund K. Q: who should receive the shingles vaccine? Cleve Clin J Med. 2009;76:48–8.
47.
Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States. Ann Intern Med. 2009;150:40–4.CrossRef
Metadata
Title
Health Maintenance and Inflammatory Bowel Disease
Authors
Catherine S. Manolakis
Brooks D. Cash
Publication date
01-10-2014
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 10/2014
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-014-0402-4

Other articles of this Issue 10/2014

Current Gastroenterology Reports 10/2014 Go to the issue

Stomach and Duodenum (J Pisegna, Section Editor)

Endoscopic Management of Bleeding Gastric Varices—an Updated Overview

Large Intestine (B Cash, Section Editor)

Common Anorectal Conditions: Evaluation and Treatment

Pancreas and Biliary Tract (O Haluszka, Section Editor)

The Treatment of Cholangiocarcinoma: a Hepatologist’s Perspective

Large Intestine (B Cash, Section Editor)

Narcotic Bowel Syndrome and Opioid-Induced Constipation

Nutrition and Obesity (S McClave, Section Editor)

When Can Nutritional Therapy Impact Liver Disease?

Nutrition and Obesity (S McClave, Section Editor)

Tips and Tricks for Deep Jejunal Enteral Access: Modifying Techniques to Maximize Success

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits